KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Clinical and Experimental Investigations / 2016 / Cilt: 7 Sayı: 1

The Effect of Elevated Homocysteine Levels on Atherosclerosis in Patients with Peritoneal Dialysis

Fatih ŞAHPAZ
Sayfa
47–51
Yayın Tarihi
2016-03-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

J Clin Exp Invest 2016; 7 (1): 47-51

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Cardiovascular disease is an important cause of morbidity and mortality in patients with renal failure.
📊
Temel Bulgular & Veri:Patients with chronic renal failure are significantly susceptible to atherosclerosis.
💡
Sonuç & Katkı:J Clin Exp Invest 2016; 7 (1): 47-51
🔬Tür:Araştırma Makalesi
📍Kapsam:2016 Verileri
⚙️Değişkenler:İnflamasyon · homosistein · intima media kalınlığı

Abstract

Objective: Cardiovascular disease is an important cause of morbidity and mortality in patients with renal failure. Patients with chronic renal failure are significantly susceptible to atherosclerosis. In the present study, we aimed to investigate the effect of elevated homocysteine on atherosclerosis and inflammation in continuos ambulatory peritoneal dialysis (CAPD) patients. Methods: 56 patients undergoing CAPD and 27 healthy subjects was enrolled in the study. All patients total cholesterol, triglyceride, LDL cholesterol, HDL cholesterol, hs-CRP, homocysteine, intima-media thickness, arterial stiffness values were measured and statistically analyzed. Results: It is determined that the levels of total cholesterol, triglyceride, LDL cholesterol, HDL cholesterol, homocysteine, intima-media thickness, arterial stiffness and hs-CRP was higher in patients compared to the control group (in order; p=0.03, p=0.0006, p=0.02). Conclusion: Carotid intima-media thickness being increased because of increased levels of homocysteine and inflammation in CAPD patients. Therefore, in case of atherosclerosis, hyperlipidemia and inflammation more aggressive treatment protocol should be considered. Patients with elevated plasma homocysteine concentrations should be treated. J Clin Exp Invest 2016; 7 (1): 47-51

🔖

Bu Makaleye Atıf Yap

ŞAHPAZ, F. (2016). The Effect of Elevated Homocysteine Levels on Atherosclerosis in Patients with Peritoneal Dialysis. Journal of Clinical and Experimental Investigations, Cilt: 7 Sayı: 1, 47–51. https://ajindex.com/articles/1001211

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Johansson AC, Samuelsson O, Attman PO, et al. Dyslipidemia in peritoneal dialysis-relation to dialytic variables. Perit Dial Int 2000;20:306-314
  2. Attman PO, Samuelsson OG, Moberly J, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536-1542
  3. Moberly JB, Attman PO, Samuelsson O, et al. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 2002;22:220-228
  4. Attman PO, Samuelsson OG, Moberly J, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536-1542
  5. Ross R. Atherosclerosis- An inflammatory disease. N Engl J Med 1999;340:115-126
  6. Aydın M, Selcoki Y, Nazlı Y, et al. Relationship between total antioxidant capacity and the severity of coronary artery disease. J Clin Exp Invest 2012;3:22-28
  7. De Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean α-linolenic asid rich diet in secondary prevention of coronay heart disease. Lancet 1994;343:1454-1459
  8. Siamopoulos KC, Elisaf M. Is CAPD atherogenic? Perit Dial Int 1997;17:227-231
  9. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with endstage renal disease. Nephrol Dial Transplant 2004;19:67- 72
  10. Özdemir FN, Güz G, Sezer S, et al. Atherosclerosis risk is higher in continuous ambulatory peritoneal dialysis patients than in hemodialysis patients. Artif Organs 2001;25:448- 452
  11. Avram MM, Fein PA, Antignani A, et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989;87:55-60
  12. Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to? Blood Purif 2005;23:72- 78
  13. Chauveau P, Chadefaux B. Hyperhomocysteinemia, a risk factor for arteriosclerosis in chronic uremic patients. Kidney Int 1993;43:72-77
  14. Bostom AG, Lathrop L. Hyperhomocysteinemia in end stage renal disease: Prevalance, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20
  15. Maeda N, Sawayama Y, Tatsukawa M, et al. Carotid artery lesions and atherosclerotic risk factors in Japanese hemodialysis patients. Atherosclerosis 2003;169:183-192
  16. Kawagishi T, Nishizawa Y, Konishi T, et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int